Private Advisor Group LLC boosted its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 32.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 308,622 shares of the company's stock after purchasing an additional 75,408 shares during the quarter. Private Advisor Group LLC's holdings in AbbVie were worth $80,732,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also added to or reduced their stakes in ABBV. State Street Corp lifted its holdings in shares of AbbVie by 1.7% during the second quarter. State Street Corp now owns 82,596,748 shares of the company's stock valued at $20,784,646,000 after purchasing an additional 1,379,232 shares during the last quarter. Fisher Asset Management LLC boosted its position in shares of AbbVie by 252.6% in the 3rd quarter. Fisher Asset Management LLC now owns 33,489,421 shares of the company's stock worth $8,760,498,000 after purchasing an additional 23,991,451 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of AbbVie by 0.7% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company's stock worth $3,590,323,000 after buying an additional 106,091 shares during the last quarter. Legal & General Group Plc purchased a new stake in shares of AbbVie in the 2nd quarter worth approximately $2,905,952,000. Finally, Deutsche Bank AG grew its stake in shares of AbbVie by 13.0% in the 2nd quarter. Deutsche Bank AG now owns 10,772,949 shares of the company's stock worth $2,710,905,000 after buying an additional 1,241,587 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company's stock.
Analyst Ratings Changes
A number of equities research analysts have recently commented on the stock. Scotiabank increased their price target on shares of AbbVie from $280.00 to $320.00 and gave the company an "outperform" rating in a report on Tuesday, October 6th. BNP Paribas Exane boosted their price objective on shares of AbbVie from $218.00 to $247.00 and gave the stock a "neutral" rating in a report on Tuesday, August 11th. Guggenheim upped their price objective on AbbVie from $288.00 to $322.00 and gave the company a "buy" rating in a research report on Monday, November 2nd. Leerink Partners increased their target price on AbbVie from $309.00 to $342.00 and gave the company an "outperform" rating in a research note on Monday, November 2nd. Finally, Weiss Ratings raised AbbVie from a "buy (b-)" rating to a "buy (b)" rating in a report on Thursday, October 8th. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, AbbVie has a consensus rating of "Moderate Buy" and a consensus price target of $299.62.
Check Out Our Latest Research Report on AbbVie
Insider Activity
In related news, EVP Jeffrey Stewart sold 40,619 shares of the business's stock in a transaction on Monday, November 9th. The stock was sold at an average price of $293.60, for a total transaction of $11,925,738.40. Following the completion of the transaction, the executive vice president owned 83,171 shares in the company, valued at $24,419,005.60. The trade was a 32.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.06% of the company's stock.
AbbVie Trading Down 2.4%
Shares of AbbVie stock opened at $285.92 on Thursday. The stock has a 50 day moving average of $277.84 and a 200 day moving average of $241.96. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $302.93. The firm has a market cap of $505.39 billion, a PE ratio of 49.21, a PEG ratio of 1.33 and a beta of 0.20.
AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings data on Friday, October 30th. The company reported $3.82 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.73 by $0.09. The business had revenue of $17.40 billion for the quarter, compared to the consensus estimate of $17.32 billion. AbbVie had a negative return on equity of 450.55% and a net margin of 15.67%. The company's revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.86 EPS. As a group, equities research analysts forecast that AbbVie Inc. will post 13.98 earnings per share for the current fiscal year.
AbbVie Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 16th. Investors of record on Friday, January 15th will be paid a dividend of $1.82 per share. The ex-dividend date of this dividend is Friday, January 15th. This represents a $7.28 dividend on an annualized basis and a dividend yield of 2.5%. This is an increase from AbbVie's previous quarterly dividend of $1.73. AbbVie's dividend payout ratio is 119.10%.
AbbVie Profile
(
Free Report)
AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.
Featured Stories
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AbbVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.
While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.